iShares S&P Small-Cap 600 Growth
Is Tesla Bear Jim Chanos Buying Something New?
Jim Chanos, the founder and president of Kynikos Associates, is a long-time short-seller of Tesla stock. Tesla stock has fallen 17.5% in the last year.
Evercore’s Long-Term Commitment to Shareholders
Evercore (EVR) has been very committed to rewarding its shareholders in the form of dividends as well as buybacks.
Evercore: Fall in Investment Management Revenues Continues
Evercore’s (EVR) investment management revenue in 4Q17 fell 26% to $13.2 million compared to $18 million in 4Q16.
Evercore in 4Q17: Tax Impact, Advisory Revenue, and More
Evercore’s (EVR) revenues were $540 million in 4Q17, or 21% higher than 4Q16. Revenues of $1.7 billion for 2017 was 18% higher than 2016.
Understanding MiMedx Group’s Zealous Focus on Sales
MiMedx focuses on marketing efforts to increase revenues. The company has at its disposal a sales force of 320 professionals.
Sucampo Pharmaceuticals’ Amitiza: Its Competitive Landscape
In the branded prescription category, Amitiza competes with Ironwood Pharmaceuticals (IRWD) and Allergan’s (AGN) Linzess.
Nektar Therapeutics: Positive Data from Phase 3 NKTR-181 Trial
Nektar Therapeutics’ (NKTR) NKTR-181 has already received fast-track designation from the FDA (U.S. Food & Drug Administration).
Key Risks Facing PetMed Express in 2017
PetMed Express (PETS) stock has risen 77% in the last one-year period, reaching a high of $50.06 on July 26, 2017.
Captisol-Enabled Prexasertib May Be Major Growth Driver for Ligand
Eli Lilly’s (LLY) Captisol-enabled drug Prexasertib is currently being evaluated in multiple oncology indications such as head and neck cancer, small-cell lung cancer (or SCLC), and advanced metastatic cancer.
Fully Funded Partnerships May Drive Growth for Ligand Pharmaceuticals
Ligand Pharmaceuticals (LGND) expects its licensees to invest ~$2.0 billion for advancing more than 155 partnered research and development programs in 2017.
Flotek Industries’ Current Valuation versus Its Peers
Sell-side analysts expect Flotek’s adjusted EBITDA to rise sharper in the next four quarters compared to its peers.
Weighing Flotek’s Current Valuation against Peers
Sell-side analysts expect FTK’s adjusted EBITDA to rise more sharply over the next four quarters than those of its peers.
How Flotek Industries Is Valued versus Peer Stocks
Core Laboratories (CLB) is the largest company by market capitalization among our set of select oilfield services and equipment (or OFS) companies…
How Does Take-Two Interactive Software View Fiscal 2017?
US-based Take-Two Interactive Software (TTWO) expects non-GAAP revenues in the range of $225 million–$260 million in fiscal 1Q17.
The Word on the Street: How Analysts See Papa John’s
Analysts are maintaining a price target of $67.6 for Papa John’s for the next 12-months, which represents a return potential of 2.5% for the company.
Why Are So Many Analysts Rating B&G Foods a ‘Hold’?
Approximately 78% of analysts rate B&G Foods a “hold,” and 22% rate it a “buy.” None of the analysts rate it a “sell.”
Analysts Have Revised EPS Estimates for B&G Foods: Why?
B&G Foods’ (BGS) earnings estimates have been on an upward trend since its fiscal 1Q16 impressive results. The Green Giant acquisition contributed to the results.
What Do Analysts Recommend for Texas Roadhouse?
The rise in EPS estimates for the next four quarters has prompted analysts to increase their price target for TXRH for the next 12 months to $45.1 from their earlier estimate of $44.8.
What Has Hormel Foods Planned for Fiscal 2016?
Hormel Foods (HRL) announced a 16% increase in its annual dividend, effective fiscal 2016. The annual dividend is now raised to $1.16 per share to be paid in fiscal 2016.
What Are Analyst Recommendations for Vasco Data Security?
Vasco Data Security (VDSI) has generated returns of -25.5% in the trailing 12 months and 3.0% in the trailing-one-month period.